In this study we compared the outcomes of the everolimus-eluting stent (EES) versus the zotarolimus-eluting stent (ZES) in patients treated at a tertiary medical center, with up to one year of follow-up. Methods: Unselected consecutive patients were retrospectively recruited following stenting with the ZES (n = 197) or EES (n = 190). The first 100 consecutive patients in each cohort underwent syntax scoring. The primary endpoint of the study was target vessel failure, defined as the combined endpoint of cardiac death, non-fatal myocardial infarction, or target vessel revascularization. Secondary endpoints included target lesion revascularization, target lesion failure, acute stent thrombosis, total death, cardiac death, and non-fatal myocardial infarction.
Introduction
The zotarolimus-eluting stent (ZES), Endeavor ® (Medtronic, Minneapolis, MN) and the everolimus-eluting stent (EES), Xience ® or Promus™ (Abbott Laboratories, Abbott Park, IL) are second-generation drug-eluting stents with lower target lesion revascularization and adverse event rates than bare metal stents. [1] [2] [3] [4] The ZES and EES stents have been compared in randomized trials with the paclitaxel-eluting stent (Boston Scientific, San Diego, CA) and the sirolimus-eluting stent (Cordis Corporation, Bridgewater, NJ), [5] [6] [7] but few comparative data exist between the Endeavor ZES and the EES. Herrador et al 8 compared the ZES and EES in coronary bifurcating lesions, and found higher 12-month adverse event and target lesion revascularization rates in the ZES group. Recently, a new ZES, the Resolute™ (Medtronic, Minneapolis, MN) was compared with the EES in a large randomized trial, with no differences in outcomes found between these two stents. 9 However, the Resolute ZES had prolonged elution of the drug compared with the Endeavor ZES. Compared with historic controls, the Resolute ZES stent outperformed the Endeavor ZES stent, with superior target lesion and vessel revascularization. 10 In this single-center study, we compared the Endeavor ZES and the EES for late outcomes at one year in an unselected consecutive group of patients.
Materials and methods
Unselected consecutive patients were retrospectively recruited from a single center following stenting with the ZES or the EES. Both de novo and restenotic lesions were included. Patients with bypass graft stenting or who received mixed stents were excluded. The first 100 consecutive patients in each cohort underwent Syntax scoring by an independent investigator blinded to patients' outcomes. The investigator underwent basic training in Syntax scoring using the online tutorial on the Syntax score website (http://www. syntaxscore.com) followed by extensive training with an interventional cardiologist experienced in Syntax scoring and having performed over 50 cases with close supervision. Tables 1 and 2 show the demographic, clinical, and procedural variables collected by reviewing medical records. Angiographic variables are shown in Table 2 , and were obtained by independent reviewing of the angiograms by an investigator blinded to patient outcomes. Ejection fraction was obtained from the procedural records as assessed qualitatively during the index procedure using left ventriculography.
Follow-up was limited to one year from the index procedure and was performed using medical records, phone calls, or both. Patients were initially mailed a brief letter describing the protocol, followed by a phone call to obtain verbal consent to be part of the study (using a standardized script approved by our institutional review board). All events reported by patients were verified by cross-reference to medical records. Patients who were deceased had their death certificate retrieved when possible to evaluate the cause of death.
The primary outcome of the study was target vessel failure (defined as cardiac death, non-fatal myocardial infarction, and target vessel revascularization). Secondary outcomes included target lesion revascularization, target vessel revascularization, target lesion failure (defined as cardiac death, non-fatal myocardial infarction, and target lesion revascularization), acute stent thrombosis as defined by the Academic Research Consortium, 11 non-fatal myocardial infarction, and cardiac death.
Statistical analysis
Descriptive analysis was performed on all variables. The t-test was used for continuous variables and Chi-square testing for dichotomous variables. Univariate analysis compared the demographic, clinical, angiographic, and 
Results
A total of 235 ZES and 208 EES patients met the inclusion criteria and were recruited to the study. Patients were excluded if they refused to give the verbal consent required by the institutional review board (n = 25 ZES, n = 10 EES) or were lost to follow-up (n = 13 ZES, n = 8 EES). A total of 197 ZES patients (270 vessels, 403 segments) and 190 EES patients (306 vessels, 479 segments) were included in the final analysis.
Descriptive analysis for all patients is shown in Table 1 . There was a high proportion of patients who had had prior percutaneous coronary intervention and prior bypass surgery in both cohorts. Approximately two thirds of the patients were current or prior smokers and 36.5% were diabetics. There were no statistical differences for any of the clinical and demographic variables between the EES and ZES stents, except for a higher incidence of prior myocardial infarction in the EES group (38.9% versus 28.9%; P = 0.041) and a higher incidence of cerebrovascular disease in the ZES group (16.2% versus 4.7%; P = 0.001). Also, there was no bias regarding utilization of particular stent types at the medical center between the 11 interventionalists, who used the ZES and EES at the same statistical frequency.
Indications for the procedure were similar between the two groups, with about half the patients treated for an acute coronary syndrome. The distribution of disease was also similar between the cohorts, with 6%-10% of patients having had their left main stem treated (Table 2 ). Angiographic and procedural variables are shown in Table 3 . There was a relatively high number of stents placed per patient (2.8-2.9 stents), and approximately one third of patients had restenotic index lesions. Patients in the EES group had a lower ejection fraction than those in the ZES group (51.5% versus 59.7%, P = 0.001); however, ejection fractions were in the normal range in both groups. Long lesion lengths were noted, but were similar in both groups. The Syntax scores for the first 100 consecutive patients, which reflect angiographic complexity, were statistically nearly identical between the EES and ZES (19.6 ± 12.8 versus 20.6 ± 13.6).
At one-year follow-up, target vessel failure was 26.7% for the ZES versus 20.8% for the EES (P = 0.19, Figure 1 , Table 4 ). The secondary endpoint of target lesion revascularization (20.6% versus 8.9%, P = 0.003) was superior for the ZES versus the EES. Target vessel revascularization (26.7% versus 20.8%), cardiac death (2.0% versus 1.6%), non-cardiac death (2.1% versus 1.1%), and definite and probable stent thrombosis (2.5% versus 0%) trended in favor of the EES, but no statistical difference was seen.
Clinical history of patients with definite or probable acute stent thrombosis Five patients in the ZES cohort had definite or probable stent thrombosis. The first patient was a 92-year-old female with a prior myocardial infarction and a history of hypertension. Stent thrombosis occurred 7 days after the index procedure. She was on clopidogrel and aspirin. She underwent target lesion revascularization but later died during the same 
Discussion
In this study, the primary outcome occurred in 20.8% of the EES versus 26.7% of the ZES (P = 0.19) patients, with no differences in the secondary outcome of target vessel revascularization (18.9% versus 25.6%, P = 0.142). However, the EES showed superior target lesion revascularization (8.9% versus 20.6%, P = 0.003) and target lesion failure (11.7 versus 22.6%, P = 0.003) when compared with the ZES. Both the ZES and EES have been shown to have lower target lesion revascularization and adverse event rates than bare metal stents. [1] [2] [3] [4] However, not all drug-eluting stents have similar outcomes. In this study, the EES had a superior one-year outcome than the ZES, with less target lesion revascularization and target lesion failure at the one-year follow-up. However, interestingly, target vessel revascularization was the same in both cohorts, resulting in statistically similar target vessel failure. In this retrospective study, there were no predefined endpoints as to when target lesion revascularization could be performed. It is possible that this biased the data in favor of the EES, considering that the ZES is known to have higher late lumen loss than the EES. 
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The ZES has been compared with the sirolimus-eluting stent in randomized trials. 5 Insegment binary angiographic restenosis was higher in the ZES cohort (11.7% versus 4.3%, P = 0.04). At 9 months, total (clinically and non-clinically driven) target lesion revascularization rates were 9.8% and 3.5% for the ZES and sirolimus-eluting stent groups, respectively (P = 0.04). However, clinically driven target lesion revascularization and target vessel failure did not differ significantly between the two stents. Further, the Endeavour ZES has been compared with the paclitaxel-eluting stent in the randomized ENDEAVOR IV trial. This trial showed that the ZES was noninferior to the paclitaxel-eluting stent at the 12-month follow-up, with rates of target vessel failure being 6.6% versus 7.1%, respectively (P # 0.001). In Endeavor IV, there were no significant differences between the ZES and the paclitaxel-eluting stent for rates of cardiac death, myocardial infarction, target vessel revascularization, or stent thrombosis. 13 At 3-year follow-up, compared with the paclitaxel-eluting stent, the ZES showed reduced target vessel failure (12.3% versus 15.9%, P = 0.049) and myocardial infarction rates (2.1% versus 4.9%, P = 0.005), with similar ischemia-driven target lesion revascularization (6.5% versus 6.1%, P = 0.662). 14 The EES was also compared with the paclitaxel-eluting stent in the SPIRIT III trial. At the 2-year follow-up, compared with the paclitaxel-eluting stent, patients treated with the EES had a significant 32% reduction in target vessel failure (10.7% versus 15.4%, P = 0.04) and a 45% reduction in major adverse cardiac events (cardiac death, myocardial infarction, or target lesion revascularization; 7.3% versus 12.8%, P = 0.004). 7 In the elderly cohort (those .65 years of age) of SPIRIT III, the EES-treated patients had lower rates of binary insegment restenosis (3.4% versus 15.5%, P = 0.004) at 8 months, and a 48% lower incidence of 3-year target vessel failure (10.8% versus 20.8%, P = 0.009). 15 However, limited comparative data exist for the Endeavor ZES and the EES. Herrador et al 8 compared the ZES with the EES in coronary bifurcating lesions, and found a higher 12-month adverse events rate (23.1% versus 4.5%, P , 0.001) and higher target lesion revascularization (17.5% versus 3.2%, P , 0.001) in the ZES group. Our study included consecutive patients who received EES and ZES from the same medical center. EES outperformed the Endeavor ZES at the one-year follow-up, with less target lesion failure, driven mostly by less target lesion revascularization. However, target vessel failure was similar between the two stents at one year. Recently the new Resolute ZES (Medtronic) was compared with the EES in a large randomized trial and no differences in outcome were found between these two stents. 9 However, the Resolute ZES showed prolonged elution of the drug 10 The longer drug elution time of zotarolimus seems to be a key factor in reducing target lesion revascularization and target vessel failure in patients treated with ZES stents. The Resolute ZES stent has recently entered the US market and is likely to replace the Endeavor ZES.
Overall, the rates of target lesion revascularization and target vessel failure with the ZES in our study are higher than that in the data published for the Endeavor ZES from the real-world prospective, multicenter E-Five registry. 1 The one-year outcome of the Endeavor ZES in the E-Five registry showed a target lesion revascularization rate of 4.5% and definite/probable stent thrombosis of 0.6%. Our data showed a higher target lesion revascularization and stent thrombosis rate than the E-Five registry, likely secondary to the more complex patients treated at our center. Compared with E-Five, our study had more bifurcating lesions (45.6% versus 18.9%), ostial lesions (8.3% versus 5.8%), instent restenosis (33.3% versus 4.8%), left main stenting (6.3% versus 2.4%), and longer total lesion length (54 ± 37.4 versus 18.51 ± 10.61). Furthermore, there were higher clinical risk features in our patients, with more prior percutaneous coronary interventions (67.5% versus 25.3%) and bypass surgeries (21.8% versus 7.5%). As disease complexity increases and major adverse event rates increase, it is more likely that small differences between drug-eluting stents would become more obvious and significant.
Study limitations
This study is limited by its retrospective nature. However, angiographic complexity was assessed using Syntax scoring by an investigator blinded to patient outcomes and showed no differences between the two cohorts. Interobserver and intraobserver variability was not determined in this study. However, we utilized a reliable training method recently shown to yield at least moderate agreement in Syntax calculation. 16 We also limited Syntax scoring to the first consecutive 100 patients in each cohort. However, the near identical results and similar angiographic variables between the two cohorts predict a low likelihood that differences will emerge in calculating syntax scores for the entire cohort.
It is unlikely that randomized trials will compare the Endeavor ZES with the EES because of the recent introduction of the Resolute ZES to the United States, which has proven superior results to the Endeavor ZES. However, these data continue to be of significance for patients who have already received the ZES and continue to receive the EES.
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